Control Group (n = 15)
|
Sleeve Gastrectomy Group (n = 20)
|
---|
Ceramide (ng/ml)
|
Preop
|
Po Day 1
|
Po Day 30
|
Preop
|
Po Day 1
|
Po Day 30
|
---|
C16 CER (d18:1/16:0)
|
4107,02 ± 461,12
|
4568,07 ± 265,51
|
4080,22 ± 503,81
|
3397,68 ± 217,02
|
3892,78 ± 401,89
|
3447,04 ± 183,08
|
C18 CER (d18:1/18:0)
|
1312,73 ± 198,25
|
1498,11 ± 144,02
|
1103,22 ± 182,85
|
1188,98 ± 109,14
|
1361,44 ± 203,41
|
1213,58 ± 84,05
|
C20 CER (d18:1/20:0)
|
1062,13 ± 145,50
|
1130,25 ± 125,52
|
983,98 ± 145,01
|
734,67 ± 79,31
|
762,52 ± 158,10
|
650,10 ± 77,73
|
C22 CER (d18:1/22:0)
|
6273,70 ± 851,29
|
6372,18 ± 916,66
|
7144,98 ± 899,62
|
5374,87 ± 440,21
|
3850,60 ± 471,05a,b
|
3287,03 ± 371,39c,d
|
C24 CER (d18:1/24:0)
|
19,706,45 ± 1892,46
|
22,071,44 ± 3507,56
|
24,340,62 ± 3289,63
|
20,507,48 ± 2366,78
|
14,240,44 ± 1709,18e,f
|
12,307,39 ± 1400,13g,h
|
- Values are mean ± SEM. Preop, preoperation; Po, postoperation. C16 Ceramide (d18:1/16:0), N-palmitoyl-D-erythro-sphingosine; C18 Ceramide (d18:1/18:0), N-stearoyl-D-erythro-sphingosine; C20 Ceramide (d18:1/20:0), N-arachidoyl-D-erythro-sphingosine; C22 Ceramide (d18:1/22:0), N-behenoyl-D-erythro-sphingosine; C24 Ceramide (d18:1/24:0), N-lignoceroyl-D-erythro-sphingosine
- a, p = 0,014 vs. sleeve gastrectomy preop. Statistical analysis was done by paired t-test
- b, p = 0,008 vs. control Po Day 1. Statistical analysis was done by t-test
- c, p < 0,001 vs. sleeve gastrectomy preop. Statistical analysis was done by paired t-test
- d, p < 0,001 vs. control Po Day 30. Statistical analysis was done by t-test
- e, p = 0,005 vs. sleeve gastrectomy preop. Statistical analysis was done by paired t-test
- f, p = 0,022 vs. control Po Day 1. Statistical analysis was done by t-test
- g, p < 0,001 vs. sleeve gastrectomy preop. Statistical analysis was done by paired t-test
- h, p < 0,001 vs control Po Day 30. Statistical analysis was done by t-test